Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

6.440 +0.320 (+5.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It ↗

October 04, 2022

BARDA will pay Vir up to $1 billion to develop its experimental treatment.

Via Investor's Business Daily

Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats

October 04, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗

September 16, 2022

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.

Via Benzinga

This Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts ↗

September 14, 2022

Via Benzinga

Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment ↗

August 10, 2022

Via Benzinga

Brii Biosciences Exercises Option For Vir Biotechnology's Hepatitis B Antibody In Greater China ↗

July 05, 2022

Via Benzinga

Where Vir Biotechnology Stands With Analysts ↗

May 06, 2022

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022 ↗

September 14, 2022

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...

Via Benzinga

White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox ↗

September 02, 2022

Via Benzinga

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline ↗

May 02, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Landmark Drug Pricing Reform Bill Passes Congress House ↗

August 15, 2022

The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year...

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

11 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 10, 2022

Gainers

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For August 9, 2022 ↗

August 09, 2022

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Via Benzinga

Vir Biotechnology Earnings Preview ↗

August 08, 2022

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that Vir...

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview: Vir Biotechnology ↗

August 03, 2022

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Vir...

Via Benzinga

7 Undervalued Biotech Stocks to Buy Before They Boom ↗

July 25, 2022

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

Via InvestorPlace

Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

July 11, 2022

On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier.

Via Investor's Business Daily

Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗

July 07, 2022

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Via Investor's Business Daily

From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid ↗

June 27, 2022

More than four in 10 people in a recent survey knew of someone with long Covid.

Via Investor's Business Daily

Billionaire Bill Gates Is Betting Against TSLA Stock. Here’s Where He’s Putting His Money Instead. ↗

May 25, 2022

Earlier this year, it was revealed that Bill Gates had a half a billion dollar short position against TSLA stock. So, what is he bullish on?

Via InvestorPlace

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty ↗

May 12, 2022

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

May 12, 2022

Wells Fargo cut the price target on Ford Motor Company (NYSE: F) from $24 to $12. Ford shares fell 2.8% to $12.47 in pre-market trading.

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

May 09, 2022

What Defines a Value Stock?

Via Benzinga

Earnings Scheduled For May 5, 2022 ↗

May 05, 2022

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

Via Benzinga

Earnings Outlook For Vir Biotechnology ↗

May 04, 2022

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

All News about Vir Biotechnology, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today